Form 4: Ocular Therapeutix Director Granted Significant Equity Awards

Ocular Therapeutix, Inc. Director Seung Suh Hong was granted 14,000 restricted stock units and 44,000 stock options, increasing his beneficial ownership in the company.

Summary

• Seung Suh Hong, a Director of Ocular Therapeutix, Inc. (OCUL), received equity awards on June 11, 2025, as reported in a Form 4 filing.
• The awards consist of 14,000 restricted stock units (RSUs) and 44,000 stock options.
• Each RSU represents the right to receive one share of the company's common stock.
• The stock options have an exercise price of $8.82 per share and are set to expire on June 10, 2035.
• Both the RSUs and stock options will vest 100% on the first anniversary of the grant date (June 11, 2026) or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date, contingent upon Mr. Hong's continued service on the board.
• Following these transactions, Mr. Hong's beneficial ownership includes 46,933 shares of common stock and 44,000 stock options.
• An Exhibit 24 Power of Attorney was also filed, authorizing specific individuals to handle SEC filings on behalf of Mr. Hong.

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to a director, which is generally a neutral to slightly positive event as it aligns interests and incentivizes continued service, without indicating any negative operational or financial news.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with long-term shareholder value.
• The equity awards serve as an incentive for the director's continued service and contribution to the company.
• The increase in beneficial ownership by a director demonstrates confidence in the company's future.

Negatives

• The equity awards are subject to vesting conditions, meaning the director does not immediately fully own the shares or options.
• The grant of new equity awards could lead to minor dilution for existing shareholders upon vesting and exercise.

Risks

• The value of the granted equity awards is subject to the future performance of Ocular Therapeutix, Inc.'s stock price.
• The vesting of the awards is contingent on the director's continued service, meaning forfeiture if service ceases before vesting.

Future Outlook

The granted restricted stock units and stock options are designed to vest over the next year, contingent on the director's continued service, aligning future compensation with long-term company performance.

Management Comments

• The reporting person was granted restricted stock units ('RSUs') under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc.
• Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director, a common practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to incentivize long-term commitment and align executive interests with shareholder returns.

Comparison to Industry Standards

• Equity grants to directors, including a mix of restricted stock units and stock options, are standard compensation practices in the biotechnology industry.
• While specific grant sizes vary based on company size, director responsibilities, and overall compensation philosophy, the structure observed here is consistent with typical non-employee director compensation packages at comparable small to mid-cap biotech firms.

Corporate Governance

Related Party Transactions

• Grant of 14,000 restricted stock units and 44,000 stock options to Seung Suh Hong, a director of Ocular Therapeutix, Inc., under the company's 2021 Stock Incentive Plan.

Stakeholder Impact

• Shareholders: Minor potential for future dilution upon vesting and exercise of the equity awards; alignment of director's interests with shareholder value.
• Employees: No direct impact mentioned, but reflects standard compensation practices for board members.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Next Steps

• Continued service of Seung Suh Hong on the Ocular Therapeutix, Inc. board of directors.
• Vesting of 100% of the granted RSUs and stock options on June 11, 2026, or earlier, prior to the next annual meeting of stockholders.

Key Dates

Keywords

Ocular Therapeutix, OCUL, SEC Form 4, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Insider Transaction, Beneficial Ownership